One particular adverse effect of the drug is that it may result in gastrointestinal disturbances, and thereby affect the individual's metabolism. (17) e) How does metabolism influence clearance, bioactivity and elimination?
At times, the metabolism does tend to affect the absorption and the clearance of the drug from the system. For example, the changes in the INR or the International Normalized Ratio may happen in certain patients who have been receiving oral anticoagulants, with antibiotics, such as Moxifloxacin. The age, the state of the infectious disease, and so on are all risk factors. However, the drug does not interfere with the 1A2 subtypes of cytochrome P450 enzymes, and in the same way, there was no significant effect on apparent body clearance and also on the renal clearance of moxifloxacin on a human being. (4) f) Is the drug mainly excreted in urine or faeces?
Moxifloxacin is mainly bound to serum albumin, and it is therefore widely distributed throughout the body. It is also distributed to the saliva, nasal and bronchial secretions, and to the sinus mucosa. Therefore, the elimination rates from the tissues generally correspond with the elimination through plasma. Most of the drug is metabolized in the liver, and most of it is excreted in the feces, and a small part of it in the urine. (18)
3. Mechanism of action a) How does the drug exert its effect?
The drug Moxifloxacin, a fluoroquinolone, being a broad spectrum antibiotic, with a concentration dependent bactericidal action, exerts its mechanism by either binding to or inhibiting topoisomerase II, or the DNA gyrase, and the topoisomerase IV. These are the bacterial enzymes that are responsible for the coiling and the uncoiling of DNA, which are always required for the bacterial cell repair, and for their replication within the body. (19) b) What are the targets of the drug and what aspects of its structure relate to efficacy?
When the in vitro activity of the drug was studied, and its intracellular activities were also studied, it was found that the first step mutants bore amino acid substitutions at position 81 in the Gyr A subunit of DNA gyrase. This was indicative of the fact that moxifloxacin targets the Gyr A subunit of DNA gyrase as an initial lethal event, and this was precisely the action needed against pneumonia bacteria. (20) The third generation fluoroquinolone moxifloxacin have a typical gram positive, atypical and an anaerobic coverage as compared with the first and second generation fluoroquinolones. This is a drug that is not at all affected by bacterial efflux mechanisms because of the fact that they possess a bulky side chain moiety at position 7, which as a matter of fact, serves to affect export. It also exceeds the mutant prevention concentrations for S. Pneumoniae. (21)
Does the drug have other targets/actions other than its main therapeutic action?
Since moxifloxacin is made up or composed of a number of quinolones, and if one small alteration or variation were to be brought out with regard to one of the side chains of quinolones, then it could be said that in the entire anti-bacterial structure there would be alterations, and therefore, one should understand that the basic structure of the drug must be left as it is, so that there is no change being brought about in its efficacy. (22) It must be stated however that the mechanism of the action of quinolones is not yet fully known, and in susceptible bacterial infections, it serves to inhibit the activity of DNA gyrase. (6) d) Are there abnormalities/diseases that influence its activity?
Although it is today widely acknowledged that moxifloxacin is one of the most active fluoroquinolones that can fight against tuberculosis in vitro, relevant data about its efficacy has not yet become fully available, and, according to one particular study conducted on tuberculosis patients, it was found that calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log10 CFU per ml of sputum per day, accordingly, and this meant that the drug moxifloxacin showed an early bactericidal activity that it was possible to compare with that of an isoniazid. Therefore, it may be said that tuberculosis may be one disease that may have an impact on the activity of the drug Moxifloxacin. (23)
Moxifloxacin can be utilized for the treatment of community acquired tuberculosis, and new evidence shows that the agent may be less likely to be selected for resistant SP subpopulations, wherein this resistance may happen in a series of gradual steps, as and when the organisms start to acquire mutations in their genes which encode the two topoisomerases,...
Multidrug-Resistant Tuberculosis Tuberculosis is an airborne infectious disease caused by tubercule bacilli, spread from person to person (CDC 2011). It affects the lungs and other parts of the body, such as the brain, the kidneys and the spine. It is curable but an infected person can also die of it if he does not get proper treatment (CDC) MDRTB Multidrug-resistant tuberculosis or MDRTB is TB that does not respond to the action of
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now